EVAX News & Events

Evaxion announces new data demonstrating that AI-Immunology identifies and selects the most therapeutically relevant vaccine targets. The data will be presented at the AACR Annual Meeting in San Diego, California, on April 22. "86% of the vaccine targets included in Evaxion's personalized cancer vaccine EVX-01 trigger a tumor-specific immune response. This is a success rate much higher than what has been reported for other methods. The high number reflects a broad yet specific immune response, increasing the likelihood of strong anti-tumor effect and positive clinical outcomes," the company stated. "We are delighted with the data demonstrating again the unique capabilities of AI-Immunology in identifying and selecting relevant vaccine targets. This is a further validation of the platform as an effective tool for developing potentially transformational treatments of cancer and other diseases," says Bigitte Rono, CSO of Evaxion.

Evaxion A/S announces new data demonstrating the platform's ability to also potentially develop vaccines for glioblastoma. The data, which will be presented at the AACR Annual Meeting in San Diego, California, on April 22, is "another confirmation of how AI-Immunology can be applied across a range of different cancers as well as other diseases," the company stated. "We are excited by these new findings confirming that AI-Immunology is a unique platform for designing vaccines for many different cancer types, combining neoantigens with other types of antigens. This holds great potential for improving vaccine efficacy, and we are looking forward to discussing the data with both scientific stakeholders and potential business partners at the AACR Annual Meeting," says Birgitte Rono, CSO of Evaxion.

Evaxion (EVAX) has completed the one-year extension of its phase 2 trial with personalized cancer vaccine EVX-01 with the last patient having now had last physician visit. Patients in the trial will continue to be monitored and data prepared for expected presentation in the second half of 2026. Designed with AI-Immunology, EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma. In the first two years of the phase 2 trial, patients were treated with EVX-01 in combination with Merck's (MRK) anti-PD-1 therapy, Keytruda. In the third year, patients received EVX-01 as monotherapy, allowing an evaluation of the vaccine's effect both as stand-alone and combination treatment. Further, the three-year data may provide additional insights into potential enhanced treatment effects and durability of induced immune response. Data from the first two years of the trial demonstrated an Objective Response Rate of 75%, as 12 out of 16 patients had objective clinical responses, with four patients obtaining a complete response. Additionally, a durable clinical benefit was observed as 92% of patients were still responding at two years follow-up and no relapses were observed. In total 54% of patients had a deepened response during treatment, improving from stable disease or partial response to partial or complete response. Tumor reduction was observed in 15 out of the 16 patients enrolled in the trial. In the trial, EVX-01 induced an immune response in all patients, with 81% of the targeted neoantigens generating potent specific T-cell responses. Th e company said this high immunogenicity rate stands out as highly encouraging compared to historical observations and compares very favorably to what is seen with other approaches. These results also underline and validate the precision of the AI-Immunology platform in accurately identifying neoantigens, which leads to detectable signals in patients. Data also confirmed EVX-01 to be a well-tolerated treatment.